Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung Adenocarcinoma

被引：17

作者：

Gautschi, Oliver ^{[1
]}

Menon, Roopika ^{[2
]}

Bertrand, Miriam ^{[2
]}

Murer, Christian ^{[1
]}

Diebold, Joachim ^{[1
]}

机构：

[1] Cantonal Hosp Lucerne, Luzern, Switzerland

[2] NEO New Oncol GmbH, Cologne, Germany

来源：

JOURNAL OF THORACIC ONCOLOGY | 2020年 / 15卷 / 01期

关键词：

D O I：

10.1016/j.jtho.2019.07.027

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：E13 / E15

页数：4

共 5 条

[1] Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition [J].

Deng, Lei ;

Kiedrowski, Lesli A. ;

Ravera, Elizabeth ;

Cheng, Haiying ;

Halmos, Balazs .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) :E169-E172

[2]

Wolf J., 2018, 2018 EUR SOC MED ONC

[3] Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer [J].

Wu, Yi-Long ;

Zhang, Li ;

Kim, Dong-Wan ;

Liu, Xiaoqing ;

Lee, Dae Ho ;

Yang, James Chih-Hsin ;

Ahn, Myung-Ju ;

Vansteenkiste, Johan F. ;

Su, Wu-Chou ;

Felip, Enriqueta ;

Chia, Vincent ;

Glaser, Sabine ;

Pultar, Philippe ;

Zhao, Sylvia ;

Peng, Bin ;

Akimov, Mikhail ;

Tan, Daniel S. W. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (31) :3101-+

[4]

York Emily R, 2017, J Thorac Oncol, V12, pe85, DOI 10.1016/j.jtho.2017.02.020

[5]

Yu H, 2019, CANC RES, V79

← 1 →